Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -44.30% is 26% below its 5-year average of -35.11%, around the middle of its 5-year range (-59.55%–-19.71%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.58% above its 12-month average of -44.56%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -44.30%.
RETURN ON INVESTED CAPITAL (ROIC)
-44.30%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-44.56%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-34.28%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-35.11%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+0.58%
CURRENT VS 3Y AVG
-29.24%
CURRENT VS 5Y AVG
-26.17%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.29%
median of 484 covered companies
CURRENT VS SECTOR MEDIAN
-56.60%
vs the sector median at left
4D Molecular Therapeutics, Inc.
Market Cap
$675.41M
Return on Invested Capital (ROIC)
-44.30%
TTM Avg
-44.56%
3Y Avg
-34.28%
5Y Avg
-35.11%
Market Cap
$688.14M
Return on Invested Capital (ROIC)
-101.43%
TTM Avg
-70.16%
3Y Avg
-61.78%
5Y Avg
-52.46%
Market Cap
$698.60M
Return on Invested Capital (ROIC)
-110.62%
TTM Avg
-99.41%
3Y Avg
-74.42%
5Y Avg
-73.36%
Market Cap
$643.37M
Return on Invested Capital (ROIC)
-42.02%
TTM Avg
-66.01%
3Y Avg
-48.82%
5Y Avg
-55.42%
Market Cap
$707.86M
Return on Invested Capital (ROIC)
-73.27%
TTM Avg
-60.64%
3Y Avg
-63.77%
5Y Avg
-62.42%
Market Cap
$642.31M
Return on Invested Capital (ROIC)
-20.75%
TTM Avg
-20.15%
3Y Avg
-33.64%
5Y Avg
-24.57%
Market Cap
$709.33M
Return on Invested Capital (ROIC)
6.11%
TTM Avg
9.98%
3Y Avg
8.97%
5Y Avg
8.63%
Market Cap
$637.59M
Return on Invested Capital (ROIC)
-11.80%
TTM Avg
-7.26%
3Y Avg
-5.22%
5Y Avg
9.70%
Market Cap
$632.76M
Return on Invested Capital (ROIC)
-26.94%
TTM Avg
-40.40%
3Y Avg
-38.31%
5Y Avg
-45.27%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $675.41M | -44.30% | -44.56% | -34.28% | -35.11% |
| Annexon, Inc. (ANNX)vs › | $688.14M | -101.43% | -70.16% | -61.78% | -52.46% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | -110.62% | -99.41% | -74.42% | -73.36% |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | -42.02% | -66.01% | -48.82% | -55.42% |
| Helus Pharma Inc. (HELP)vs › | $707.86M | -73.27% | -60.64% | -63.77% | -62.42% |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -20.75% | -20.15% | -33.64% | -24.57% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 6.11% | 9.98% | 8.97% | 8.63% |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | -11.80% | -7.26% | -5.22% | 9.70% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | -26.94% | -40.40% | -38.31% | -45.27% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | N/A | -136.50% | -154.74% | -122.58% |
ROIC
-44.3%
ROE
-44.0%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -44.30% |
| 2026-03-31 | -38.24% |
| 2025-12-31 | -30.52% |
| 2025-09-30 | -59.55% |
| 2025-06-30 | -50.19% |
| 2025-03-31 | -41.59% |
| 2024-12-31 | -35.36% |
| 2024-09-30 | -29.31% |
| 2024-06-30 | -21.73% |
| 2024-03-31 | -19.71% |
| 2023-12-31 | -35.17% |
| 2023-09-30 | -30.55% |
| 2023-06-30 | -34.67% |
| 2023-03-31 | -48.87% |
| 2022-12-31 | -44.71% |
| 2022-09-30 | -39.79% |
| 2022-06-30 | -35.43% |
| 2022-03-31 | -26.02% |
| 2021-12-31 | -21.16% |
| 2021-09-30 | -29.22% |
| 2021-06-30 | -21.28% |
| 2021-03-31 | -23.30% |
| 2020-12-31 | -20.86% |
| 2020-09-30 | -62.60% |
| 2019-12-31 | -112.11% |
| 2019-06-30 | -31.32% |
| 2019-03-31 | -22.89% |
| 2018-12-31 | -11.70% |
